GLP-1 Medications and Your Eyes: What Patients Need to Know

GLP-1 receptor agonists such as Ozempic and Wegovy are now used widely for diabetes and weight management. For eye care, the key issues are diabetes control, diabetic retinopathy monitoring, rare optic nerve safety signals, and emerging research in conditions such as IIH.

What Are GLP-1 Medications?

GLP-1 receptor agonists are a class of medications that mimic a natural gut hormone called glucagon-like peptide-1. They were originally developed for type 2 diabetes but are now widely used for weight management as well.

Common GLP-1 medications include:

• Semaglutide - Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral)
• Liraglutide - Victoza (diabetes), Saxenda (weight loss)
• Exenatide - Byetta, Bydureon
• Tirzepatide - Mounjaro (diabetes), Zepbound (weight loss)

These medications work by regulating appetite, slowing digestion, and improving blood sugar control. Importantly for eye health, GLP-1 receptors are also found in the brain's choroid plexus (where cerebrospinal fluid is made), in tear glands, and in the eye itself-which is why these drugs can affect your eyes in multiple ways.

GLP-1 Medications and Intracranial Pressure (IIH)

Idiopathic intracranial hypertension (IIH) is a condition of elevated pressure inside the skull that can damage the optic nerves and cause vision loss. It primarily affects young, overweight women, and weight loss is a major long-term treatment. Diagnosis usually involves brain imaging/MRV, a lumbar puncture showing elevated pressure, and an eye exam for papilledema (disc edema); IIH without papilledema is less common but possible under formal criteria. GLP-1 medications are being studied as a possible IIH option because they may affect both weight and CSF pressure regulation.

The IIH Pressure Trial

A small randomized proof-of-mechanism trial published in Brain (2023) studied 15 women with active IIH who were randomized to receive either exenatide (a GLP-1 medication) or placebo:

• Exenatide lowered measured intracranial pressure within 2.5 hours of the first dose-before any weight loss could occur
• Patients on exenatide had a larger numerical decrease in headache days than placebo at 12 weeks, but the trial was small and not definitive for headache outcomes
• In this small trial, exenatide was reported as well tolerated, but larger safety data are needed for IIH use
• The proposed mechanism: GLP-1 receptors on the choroid plexus may reduce cerebrospinal fluid production, independent of weight loss

This small trial suggested intracranial-pressure-lowering effects beyond weight loss, but larger randomized studies are needed before GLP-1 drugs become standard IIH therapy.

Large Retrospective Study

A large study published in JAMA Neurology (July 2025) identified 44,373 IIH patients across 67 healthcare organizations, then compared matched cohorts of GLP-1 users and non-users. The results were encouraging but observational:

GLP-1 users had significantly better outcomes across the measured endpoints, but because this was an observational study, it cannot prove that the medication caused the differences.

Current Status

GLP-1 medications are not yet standard of care for IIH. The Phase 3 IIH EVOLVE trial was terminated for business reasons-not safety concerns-so larger randomized evidence is still needed. The IIH ADVANCE trial, a Phase 3 study testing tirzepatide in adults with active IIH, is ongoing at the University of Birmingham.

What makes GLP-1 medications interesting for IIH is the potential dual mechanism under study: weight loss support and possible direct effects on cerebrospinal fluid pressure. Patients with IIH often experience transient visual obscurations, headaches, and blurred vision-symptoms that may improve if intracranial pressure is controlled.

GLP-1 Medications and Diabetic Retinopathy

One of the earliest concerns about GLP-1 medications and eyes came from the SUSTAIN-6 trial (2016), which found that semaglutide was associated with a higher rate of retinopathy complications (hazard ratio 1.76) compared to placebo.

What's Actually Happening

The leading explanation is "early worsening" of diabetic retinopathy from rapid improvement in blood sugar control, rather than a direct retinal toxicity unique to GLP-1 drugs. This phenomenon was first observed in the landmark DCCT trial (1993) and formally characterized in a dedicated sub-analysis (1998), and it can happen with insulin too. When blood sugar drops quickly, the retinal blood vessels that adapted to high sugar levels can temporarily worsen before improving.

Who Is at Risk

Early worsening is primarily a concern for patients who have:

• Pre-existing proliferative diabetic retinopathy (the more advanced form)
• Poorly controlled diabetes (high HbA1c) starting intensive treatment
• These patients are at risk with any treatment that rapidly lowers blood sugar, not just GLP-1 medications

Reassuring Evidence

Multiple large studies have found no increased risk of retinopathy worsening when patients don't have severe pre-existing disease:

• A Cleveland Clinic study (2023) found no increased retinopathy risk with GLP-1 use
• An Ophthalmology Science analysis (2024) supported the idea that observed risk may relate more to rapid glucose change than to the drug class itself, but causality remains under study
• The OHDSI database study (2025) across millions of patients showed no worsening when baseline retinopathy was controlled

The FOCUS Trial (Novo Nordisk), studying 1,500 patients specifically for retinopathy outcomes, is expected to provide more targeted evidence on retinopathy outcomes.

GLP-1 Medications and NAION (Sudden Vision Loss)

Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition where blood flow to the optic nerve is suddenly disrupted, causing painless vision loss in one eye. A possible link between GLP-1 medications and NAION has generated significant attention.

The Evidence

A study published in JAMA Ophthalmology (2024) from a single medical center found a higher cumulative incidence of NAION in overweight/obese patients taking semaglutide (6.7%) compared to non-users (0.8%), with similar findings in the type 2 diabetes cohort (8.9% vs 1.8%). However, this was a retrospective, single-center study with important limitations.

Regulatory Responses

• European Medicines Agency (EMA), June 2025: Classified NAION as a "very rare" side effect (~1 in 10,000) specifically of semaglutide medicines (Ozempic, Rybelsus, Wegovy) and recommended label updates
• World Health Organization (WHO), June 2025: Issued an alert about the potential association with semaglutide
• U.S. FDA: Check current U.S. prescribing information for the latest labeling; regulatory wording has differed from the EMA's semaglutide-specific NAION classification

Important Context

NAION was already known to be associated with diabetes and obesity-the very conditions that GLP-1 medications treat. This makes it difficult to determine whether any increased risk is from the medication itself or from the underlying conditions. Larger, prospective studies are needed.

GLP-1 Medications and Glaucoma

Early observational and mechanistic research is exploring whether GLP-1 medications could affect glaucoma risk or eye pressure, but clinical benefit is not proven.

What the Science Shows

• GLP-1 receptors are present in the eye's ciliary body, which produces the fluid (aqueous humor) that determines eye pressure
• Preclinical studies suggest GLP-1 medications may inhibit aqueous humor secretion, a hypothesis for possible pressure effects
• GLP-1 signaling may improve fluid outflow via nitric oxide pathways
• Small reductions in eye pressure have been observed in GLP-1 users, though not yet clinically significant
• There is also interest in potential neuroprotective effects on retinal ganglion cells (the cells damaged in glaucoma)

Clinically, this remains an active research area. GLP-1 medications are not proven to prevent glaucoma and are not a substitute for standard glaucoma treatment. If you have glaucoma, continue your current treatment plan and discuss any questions with your eye doctor. Regular visual field testing remains essential for monitoring.

GLP-1 Medications and Dry Eye

GLP-1 receptors have been found in the lacrimal (tear) glands, raising questions about whether these medications affect tear production and dry eye.

What Studies Show

• Some research has found improved Schirmer test values (a measure of tear production) and better tear breakup time in patients taking GLP-1 medications
• This suggests GLP-1 agonists may support healthy tear production
• The effect appears to be through direct stimulation of tear gland function

The Caveat

GLP-1 medications commonly cause nausea and reduced appetite, which can lead to dehydration-a known contributor to dry eye symptoms. If you take a GLP-1 medication and experience dry eyes, staying well hydrated is particularly important. Artificial tears can help manage symptoms in the meantime.

"Ozempic Face" and Your Eyes

"Ozempic face" has become a widely discussed topic as more people use GLP-1 medications for weight loss. It is not believed to be a direct pharmacologic eye or skin effect; it is more likely related to rapid or significant weight loss.

What Is Happening

"Ozempic face" refers to the facial volume loss that can occur with rapid, significant weight loss-regardless of how that weight loss is achieved. When fat pads in the face shrink, the face can appear more gaunt or aged. Around the eyes specifically:

• Eyes may appear deeper-set as periorbital (around the eye) fat pads shrink
• The area under the eyes can appear more hollow
• Existing under-eye circles may become more noticeable

Important Context

• This is not a drug side effect-it's a consequence of significant weight loss
• Studies suggest 25-40% of weight lost on GLP-1 medications can be lean mass, which contributes to facial volume changes
• The effect is largely cosmetic, not medically harmful
• Facial volume typically stabilizes as weight stabilizes
• Some patients choose dermal fillers to restore volume, though this is a personal cosmetic choice

If you're concerned about facial changes while on a GLP-1 medication, discuss it with your doctor. Resistance training during weight loss can help preserve lean mass.

What to Tell Your Eye Doctor

If you're taking a GLP-1 medication, bring this information to your eye appointments:

Always mention your GLP-1 use-many patients don't think to mention weight loss or diabetes medications at eye exams, but it matters.

If you have diabetes:

• Request a baseline dilated eye exam before starting a GLP-1 medication
• Your doctor may recommend closer monitoring in the first 6 months, especially if you have existing retinopathy
• Bring your most recent HbA1c result

If you have IIH:

• Ask your neuro-ophthalmologist whether early GLP-1 evidence is relevant to your situation
• Discuss whether the dual mechanism (weight loss + direct pressure reduction) could benefit your situation
• Continue your current monitoring schedule including visual fields and OCT

If you notice any vision changes:

• Report them promptly to both your eye doctor and prescribing doctor
• Do not stop your medication without medical guidance
• Sudden vision loss requires immediate attention

General tips:

• Bring a list of all medications including dosages to every appointment
• Mention how long you've been on the medication and any recent dose changes

Frequently Asked Questions

Can Ozempic cause vision problems?

Ozempic (semaglutide) has been associated with a very rare risk of NAION, a form of sudden vision loss. The European Medicines Agency has classified NAION as a "very rare" potential side effect of semaglutide medicines. For most patients, the overall eye-related risks are low, but you should report any vision changes to your doctor promptly and check current U.S. labeling with your prescriber.

Should I get an eye exam before starting Ozempic or Wegovy?

If you have diabetes, a baseline dilated eye exam before starting is recommended, especially if you have existing diabetic retinopathy. For patients without diabetes or known eye conditions, a routine eye exam is always a good idea but isn't specifically required before starting GLP-1 medications.

Can GLP-1 medications help with IIH?

Early research is cautiously encouraging. The IIH Pressure Trial (Brain, 2023) suggested that exenatide lowered intracranial pressure within hours-before any weight loss occurred. Headache days improved numerically more than placebo, but the trial was small. A large observational study of IIH patients (JAMA Neurology, 2025) found better outcomes in matched GLP-1 users, but cannot prove causation. GLP-1 medications are not yet standard of care for IIH, but discuss this option with your neuro-ophthalmologist.

Will Ozempic make my diabetic retinopathy worse?

Possibly in the short term, but this isn't specific to Ozempic. Any treatment that rapidly lowers blood sugar can cause temporary "early worsening" of existing diabetic retinopathy. This risk is highest in patients with pre-existing proliferative retinopathy and poorly controlled diabetes. Your eye doctor can monitor for this with more frequent exams during the first few months.

What is the NAION risk with semaglutide?

NAION (non-arteritic anterior ischemic optic neuropathy) is sudden, painless vision loss from disrupted blood flow to the optic nerve. A single-center retrospective cohort study (Hathaway et al., JAMA Ophthalmology, 2024) reported a higher rate of NAION among diabetic and overweight/obese patients prescribed semaglutide compared with matched non-users; on this basis, the EMA classified NAION as a "very rare" side effect of semaglutide. The absolute risk in any individual patient appears small, and NAION is also associated with diabetes and obesity themselves - the very conditions these drugs treat - making causation difficult to establish. If you experience sudden vision loss, seek immediate medical attention and check current U.S. labeling with your prescriber.

Can I take Ozempic if I have glaucoma?

Current evidence has not shown that GLP-1 medications worsen glaucoma. Early research is exploring possible modest eye-pressure effects, but GLP-1 drugs are not proven glaucoma treatment. Continue your current glaucoma treatment and monitoring as directed by your eye doctor.

Does Ozempic cause dry eyes?

GLP-1 medications are not clearly proven to cause dry eyes directly. Limited research has explored possible tear-production effects, but the common side effects of nausea and reduced appetite can lead to dehydration, which can worsen dry eye symptoms. Stay well hydrated and use artificial tears if needed.

What is "Ozempic face" and does it affect my eyes?

"Ozempic face" refers to facial volume loss from significant weight loss. It is not believed to be a direct pharmacologic eye effect, and is more likely weight-loss related. Around the eyes, this can make eyes appear more deep-set and hollow. It's cosmetically concerning for some patients but not usually medically harmful. The effect often stabilizes as weight stabilizes.

References